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PENILAIAN DIABETES MELLITUS JENIS-2 DALAM KALANGAN PESAKIT 
HEPATITIS B DAN C DI HOSPITAL PULAU PINANG, MALAYSIA 
ABSTRAK 
 
Diabetes mellitus (DM) dan infeksi virus hepatitis kronik C (HCV) dan B (HBV)  secara 
relatifnya merupakan gangguan biasa dan dianggap sebagai masalah utama kesihatan 
awam di seluruh dunia, dengan meningkatnya komplikasi dan kadar mortaliti.  Kaitan 
epidemiologi antara  infeksi virus hepatitis kronik dan diabetes mellitus telah dilaporkan. 
Banyak kajian terdahulu menunjukkan prevalens DM yang amat tinggi dalam kalangan 
pesakit HCV- berpenyakit hati kronik, jika dibandingkan dengan  pesakit berpenyakit 
hati kronik yang berpunca daripada etilogi lain. Banyak kajian lain melaporkan 
perkaitan yang sama antara diabetes dan infeksi virus hepatitis B, tetapi dengan 
kekerapan yang lebih rendah.  Matlamat kajian ini adalah untuk menilai keberlakuan 
diabetes jenis-2 dalam kalangan pesakit infeksi virus hepatitis B atau C dan mengkaji 
faktor risiko yang berkaitan dengan perkembangan diabetes jenis-2 dalam populasi 
hepatitis. Kajian silang retrospektif telah dijalankan di Hospital Pulau Pinang, Malaysia. 
Seramai 520 pesakit hepatitis B dan C terlibat dalam kajian ini berdasarkan kriteria yang 
ditetapkan.  Daripada 520 pesakit, 269 mengalami infeksi hepatitis B dan 251 lagi 
mengalami infeksi hepatitis C. Rekod pesakit diteliti untuk mendapatkan data kajian, 
contohnya kewujudan diabetes jenis-2, jenis hepatitis virus kronik, data makmal, data 
demografi dan keputusan klinikal. Kajian ini melibatkan 331 pesakit lelaki dan 189 
pesakit perempuan.  Daripada jumlah tersebut, 177 berbangsa Melayu, 319 Cina dan 24 
India. Terdapat perkaitan yang signifikan antara diabetes jenis-2 infeksi hepatitis kronik, 
yang prevalens diabetes secara signifikannya lebih tinggi dalam infeksi hepatitis C 
(25.9%) daripada dalam infeksi hepatitis B (16.4%) (p = 0.008).  Selepas pemboleh ubah 
xv 
 
diselaraskan dengan menggunakan regresi logistik, kejadian diabetes dikaitkan dengan 
bangsa (OR = 3.16, 95% CI = 1.90-5.24, nilai p = 0.001), kumpulan umur (OR = 2.53, 
95% CI = 1.41-15.45, nilai p = 0.002), sejarah diabetes keluarga (OR = 3.51, 95% CI = 
1.73-7.10, p = 0.001) dan jenis hepatitis (OR = 1.70, 95% CI = 1.07-2.70, nilai p = 
0.023).  Dalam kalangan pesakit yang dijangkiti hepatitis B, kejadian diabetes dikaitkan dengan 
faktor bangsa dan kumpulan umur dalam kehadiran faktor lain.  sementara, selepas factor 
penyelarasan dalam kalangan pesakit yang dijangkiti hepatitis C dikawal, kejadian diabetes 
dikaitkan dengan bangsa dan sejarah diabetes keluarga. Dapatan kajian menunjukkan bahawa 
jenis hepatitis secara signifikannya berkaitan dengan kejadian diabetes dalam kalangan pesakit 
hepatitis B dan C, daripada populasi kajian. Selanjutnya, pesakit dengan infeksi hepatitis 
C adalah berisiko tinggi untuk mengalami diabetes jenis-2 daripada pesakit dengan 
infeksi hepatitis B. Kajian ini merumuskan bahawa pesakit berbangsa Melayu, berumur 
(lebih tua), serta dengan sejarah diabetes keluarga yang positif, dianggap sebagai  faktor 
risiko bebas bagi perkembangan diabetes mellitus jenis-2 dalam kalangan pesakit yang 
dijangkiti virus hepatitis. Kajian selanjutnya diperlukan untuk mengkaji  perkaitan ini 
serta faktor-faktor yang risiko lain. Di samping itu, kajian ini juga mencadangkan agar 
penyaringan ketidaknormalan glukosa dijalankan dalam kalangan pesakit dengan infeksi  
hepatitis C. 
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EVALUATION OF TYPE-2 DIABETES MELLITUS AMONG HEPATITIS B 
AND C PATIENTS IN PENANG GENERAL HOSPITAL, MALAYSIA 
ABSTRACT 
 
Diabetes mellitus (DM) and chronic hepatitis C (HCV) and B (HBV) virus infections are 
relatively common disorders and considered as worldwide, major public health problems 
with increasing complication and mortality rates. An epidemiologic link between 
chronic hepatitis virus infection and diabetes mellitus has recently been reported. Many 
of previous studies have revealed a higher prevalence of DM in patients with HCV-
related chronic liver disease when compared to patients with chronic liver disease 
resulting from other etiologies. Many other studies have reported similar relationship 
between diabetes and hepatitis B virus infection but with lower frequencies. The aims of 
this study are to evaluate the occurrence of type-2 diabetes among patients with chronic 
hepatitis B or C virus infections and to investigate the risk factors which are associated 
with the development of type-2 diabetes in hepatitis population. A retrospective cross-
sectional study was conducted in Penang General Hospital, Penang, Malaysia. A total of 
520 patients with hepatitis B and C were enrolled in this study according to the inclusion 
criteria of the study. Among 520 patients, 269 were diagnosed with chronic hepatitis B 
and 251 with chronic hepatitis C infection. The patients’ records were reviewed to select 
the required data for the study such as the presence of type-2 diabetes, type of chronic 
viral hepatitis, laboratory data, demographic data and clinical outcomes. This study 
included 331 males and 189 females. Out of those, 177 patients are Malay, 319 Chinese 
and 24 Indian. There was a significant association between chronic hepatitis infection 
type-2 diabetes, in which, the prevalence of diabetes was significantly higher in hepatitis 
C (25.9%) than in hepatitis B (16.4%) infection (p = 0.008). After adjusting the 
xvii 
 
confounding variables by applying logistic regression, diabetes occurrence was associated with 
race (OR = 3.16, 95% CI = 1.90-5.24, p value = 0.001), age group (OR = 2.53, 95% CI = 
1.41-15.45, p value = 0.002), family history of diabetes (OR = 3.51, 95% CI = 1.73-
7.10, p = 0.001) and type of hepatitis (OR = 1.70, 95% CI = 1.07-2.70, p value = 0.023). 
Among hepatitis B infected patients, diabetes occurrence was related to the race and age 
group factors in the presence of other factors. While after controlling of confounding 
factors among hepatitis C infected patients, diabetes occurrence was associated with the 
race and family history of diabetes. The study findings revealed that type of hepatitis 
was significantly associated with the diabetes occurrence among hepatitis B and C 
patients of the study population. Furthermore, patients with hepatitis C infection were at 
a higher risk to develop type-2 diabetes than patients with hepatitis B infection. This 
study concluded that the Malay race, older age and positive family history of diabetes 
are considered as independent risk factors for type-2 diabetes mellitus development 
among viral hepatitis infected patients. Further studies are needed on this field to 
investigate this association and the other possible risk factors. In addition, this study 
suggests that screening for glucose abnormalities should be indicated in patients with 
hepatitis C infection. 
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Chapter One 
Introduction 
 
1.1   Viral Hepatitis 
Hepatitis is defined as an inflammation of the liver. There are many causes of hepatitis 
including viruses, medicines and alcohol. However, the hepatitis which is caused by a 
virus is usually called viral hepatitis. There are two phases of viral hepatitis; acute 
hepatitis which is found in all types of hepatitis, and chronic hepatitis which is observed 
in hepatitis B, C and D infection only (Horn, 2005). Most forms of hepatitis can clear up 
spontaneously within few months, while other cases having certain types of hepatitis can 
develop chronic and fatal liver diseases (Carlson et al., 2004).  
 
Chronic hepatitis is considered as a heterogeneous group of diseases of different 
etiologies, pathogenesis and degree of activity as well as stage of progression (Kuntz 
and Kuntz, 2008). The numbers of hepatitis infection cases (especially B and C) are 
staggering since both are common infectious diseases with many ways of virus 
transmission among the general population. Moreover, the diagnosis and treatment of 
hepatitis represent the most active part of medicine related to the liver disease, and this 
is due to the development of basic molecular biology and the large numbers of infected 
people. The knowledge of viral hepatitis infection is increasing especially for hepatitis C 
virus which was discovered about 15 years ago. The recent available information of viral 
hepatitis makes it possible to understand the majority of hepatitis viruses and the related 
diseases (Worman, 2006).  
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1.2   Hepatitis Classification  
There are many types of human hepatitis viruses namely: hepatitis A virus, hepatitis B 
virus, hepatitis C virus, hepatitis D virus, and hepatitis E virus and the diseases which 
caused by these viruses are known as hepatitis A, hepatitis B, hepatitis C, hepatitis D 
and hepatitis E, respectively (Hollinger et al., 2002).  
 
Different types of human hepatitis viruses cause different types of liver diseases and 
there many ways to classify these viruses. The classification may depend on the viruses 
DNA and RNA or could be based on the families of viruses that they belong to. On the 
other hand, the clinicians may divide them according to the types of hepatitis they can 
cause. While for epidemiologists, they more interested in the transmission ways of 
hepatitis viruses (Worman, 2006). 
 
Hepatitis B and C viral infections are considered the most important types of hepatitis 
and major health problems in the world. These two viruses are mostly associated with 
chronic hepatitis, liver cirrhosis and hepatic failure and sometimes may progress to 
hepatocellular carcinoma. Moreover, they are known to cause infections with significant 
morbidity and mortality especially in developing countries (Haider et al., 2006). 
 
1.2.1  Hepatitis B Infection 
Hepatitis B is an infectious disease and it is caused by hepatitis B virus (HBV) which 
can attack the humans liver leading to transient or chronic infection (Seeger and Mason, 
2000). HBV was discovered in 1966 (Lee, 1997).  
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The infection of HBV was firstly known as “serum hepatitis” (Yap, 2004). This virus 
can replicate itself inside the hepatocytes causing an overlapping with the normal 
functions of the liver (Tong et al., 1999). HBV infection is considered as a world health 
problem especially in Asia and its progression can lead to significant morbidity and 
mortality. However, HBV can be transmitted by contact to the infected blood or body 
fluids (Lavanchy, 2004). HBV infection can be in acute or chronic phases, in which, the 
symptoms of acute HBV infection include vomiting, abdominal pain, nausea, fever, 
jaundice, dark urine and hepatomegaly. Around 90% of perinatal acute hepatitis B 
infection cases are asymptomatic. The typical symptoms are well reported in about 5 – 
15% of recently infected young children (1–5 years of age) and in 33-50% of older 
children adolescents and adults (Shepard et al., 2006). The majority of acute hepatitis B 
infected individuals are capable to clear the viral infection without medicines and they 
virtually have immunity to the HBV (Maddrey, 2000). Among these infected 
individuals, approximately 5-10% of people with acute infection will develop chronic 
HBV infection (Jonas et al., 2010).   
 
The infected individuals with chronic HBV have a higher risk to develop liver cirrhosis, 
end stage liver disease and hepatocellular carcinoma which can occur as a result of 
immune-mediated inflammatory response. Approximately 12% of patients with chronic 
HBV infection have been reported to develop cirrhosis annually (Pungpapong et al., 
2007; Yin and Tong, 2006). Moreover, patients with chronic HBV infection have higher 
risk for hepatocellular carcinoma in about 300-fold when compared with the general 
population (Wong et al., 1995). 
4 
 
Chronic HBV infection causes many complications and it bears the burden of several 
diseases which are virtually associated with HBV. Many studies have reported that 
cirrhosis and hepatocellular carcinoma can lead to premature death in 5-15% of chronic 
HBV infected patients. Hepatic manifestations which are related to HBV infection can 
still be asymptomatic until the diagnosis or until they present the acute hepatitis signs 
(Shepard et al., 2006). 
  
Approximately 2 billion people have been infected with HBV in the world. Among 
them, there are 350 million people who are diagnosed with chronic HBV infection, and 
about 30% of them will develop chronic infection complications leading to death 
(André, 2000). The prevalence of HBV infection can be divided into low, intermediate 
and high endemicity (Rots et al., 2010). In Asia, the prevalence is considered high and it 
is estimated to be less than 8% in many countries like China, Indonesia, Korea and 
Philippine (Yin and Tong, 2006). 
 
The situation does not differ so much in Malaysia since the viral hepatitis is considered 
as a serious public problem and it is estimated that 1 million people are infected with 
chronic HBV. Moreover, the prevalence of HBV infection is 4.7% and it constitutes 
about 75% of all viral hepatitis in the Malaysian population. Approximately 80% of the 
hepatocellular carcinoma cases are attributed to chronic HBV infection in Malaysia 
(Khairullah and Merican, 2004; Yin and Tong, 2006). 
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There are many routes by which HBV can transmit among the people. Blood transfusion 
is considered as the main route followed by sexual transmission. While in the endemic 
regions, the perinatal vertical transmission is a common way of spread. On the other 
hand, there are many other potential routes of virus transmission including needle stick, 
dialysis and transplacental spread (Lamoreux, 2008). 
 
The drugs that are used in the treatment of HBV infection have been reported to reduce 
the liver damage by stopping virus replication but not to clear the infection (Dienstag, 
2008). In acute HBV infection, the majority of patients do not need a treatment because 
they can clear the infection without any treatment especially in adults (Hollinger and 
Lau, 2006).  
 
HBV infection drugs include mainly interferon which is defined as an immune system 
modulator. The other type of chronic HBV infection drugs of antiviral agents included 
lamivudine, adefovir, tenofovir and entacavir (Dienstag, 2008). However, the antiviral 
therapy of HBV infection is expensive, therefore, it is not easy for the treatment to be 
available for the majority of the infected patients in the developing countries (Wong et 
al., 1995). 
 
The prevention of hepatitis infection by the vaccine is the most meaningful way to avoid 
the occurrence of viral hepatitis. Thus, all the infants have to obtain the hepatitis 
vaccine. Since 1982, the vaccine of HBV infection was used worldwide and about 1 
million doses have been used. In several countries, the percentage of children who have 
chronic HBV infection is about 8-15% and the vaccination has minimized the chronic 
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infection rate in immunized children to less than 1% (WHO, 2008). Malaysia has a 
successful program of vaccination, therefore, the incidence of viral hepatitis infection 
has been reduced significantly (André, 2000). 
 
1.2.2  Hepatitis C Infection 
Hepatitis C virus (HCV) causes hepatitis C which is considered as a blood liver disease, 
this virus was first discovered in 1989. Initially, the disease was known as "non-A non-
B".  HCV is transmitted primarily by direct contact with the blood or body fluids of the 
infected individuals. However, HCV infection is considered as a cause for chronic liver 
disease such as liver cirrhosis (Sy and Jamal, 2006). 
 
Moreover, HCV leads to liver inflammation that interferes with normal liver functions. 
Eventually, HCV can lead to severe, persistent liver damage, cirrhosis and may be 
complicated by liver cancer. The initial symptoms of HCV infection are mild and 
because of that the infection often goes unnoticed until the damage of the liver is 
discovered after years of infection (WHO, 2003).  
 
Approximately more than 170 million of the world's population is currently diagnosed 
with chronic HCV infection and it is also responsible for 100000 cases of liver cancer 
per year (Poynard et al., 2003). Therefore, World Health Organization (WHO) has 
considered HCV infection as a global health problem. Because of this high prevalence of 
HCV infection and to recognize its epidemiology, there is a global concern of the 
disease in order to identify the specific health care measures to provide disease 
prevention and control (Chen and Morgan, 2006). 
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Primary exposure to HCV causes an acute infection which is often relatively mild. Most 
patients who have chronic HCV infection do not show the symptoms and they live with 
a normal life. In 10-25% of people, the infection develops over the course of 10-40 years 
(Alter et al., 1998). Some of infected individuals with acute hepatitis might have mild 
flu-like symptoms, including loss of appetite, fever, headaches, abdominal pain, muscle 
or joint pain, nausea and fatigue (Villano et al., 1999). On the other hand, some others 
with chronic infection, though not common, they showed more severe flu-like 
symptoms, itching and dark urine (Hoofnagle, 1997). About 20-30% of infected persons 
develop clinically acute HCV infection in their attempt to resolve the infection, while 
70-80% of patients with acute HCV infection do not resolve the infection but lead to 
permanent viral infections (Immunobiology, 2005).  
 
Over time, people with chronic HCV infection may report various symptoms related to 
liver damage (Chen and Morgan, 2006). Chronic HCV infection accounts for at least 
25% of all cases of chronic liver disease. However, a significant proportion of infected 
individuals with chronic HCV infection are asymptomatic, in which, patients have 
normal liver enzymes and normal liver histology. Progression of HCV is slow in 
infected patients, and they may remain asymptomatic for many years (Desenclos et al., 
2001). The prognosis of chronic HCV infections may be liver cirrhosis and 
hepatocellular carcinoma (Bonkovsky and Mehta, 2001). Moreover, HCV-related liver 
cirrhosis is currently considered as the main cause of liver transplantation among liver 
diseases (Berenguer and Wright, 1999). 
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However, most of the chronic HCV cases eventually develop to liver disease, therefore, 
the crucial aim is to prevent the progression of HCV infection in order to minimize its 
morbidity and mortality among the infected patients (Jaeckel et al., 2001). 
  
Given the lack of HCV infection symptoms and definitive liver histology, the liver 
enzymes levels are currently considered as the main indicator of liver progression to 
cirrhosis (Hu et al., 2004). Many studies reported that severe hepatic fibrosis, as well as 
a severe inflammation activity, due to high levels of liver enzymes may be related with 
liver progression to cirrhosis over 10 years. When the fibrosis is mild, the progression to 
cirrhosis has been slowed and limited (Desenclos et al., 2001). Hence, persons with high 
levels of liver enzymes progress heading more quickly toward the disease than those 
with normal levels of the same liver enzymes (Hu et al., 2004). The HCV has a 
serological association with end-stage liver disease that needs for liver transplantation 
(Resnick and Koff, 1993). HCV infection accounts for 20% of cases of acute hepatitis, 
70% of cases with chronic hepatitis, 40% of cases of end-stage cirrhosis, 60% of cases 
of hepatocellular carcinoma and 30% of cases with liver transplant (Mchutchison et al., 
2000). 
 
HCV infection prevalence is not well known in several countries and that may be due to 
the HCV detection process which has practical difficulties involving the detection of 
HCV-RNA in the infected persons’ serum. However, based on several studies, 
approximately 3% of the total population is infected with HCV infection in the world 
(WHO, 2006). The HCV infection prevalence rate is estimated fewer than 2.5% in most 
populations in Europe, Americas, and South-East Asia.  
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The prevalence rates in Western Pacific regions and parts of South America are higher 
ranging between 2.5- 4.9% while in the Middle East and Africa the HCV infection 
prevalence rate has been reported with range between 1- 12% (WHO, 2000). 
 
In Malaysia, HCV infection prevalence is estimated 1.6% of the population (Sultan et 
al., 2010) and 0.3% is positive for anti-HCV among blood donors. Blood donation 
screening has started since 1991 in the National Blood Bank (Zawawi, 2004). HCV 
infection is a growing problem in the Malaysian population as many people are found to 
have HCV infection through routine screening. In 2000, around 550 cases were reported 
to have hepatitis C infection in Malaysia with an incidence rate of 2.5/100,000 
population. In 2004, about 741 cases were with an incidence rate of 2.9/100,000 
population. Most of these cases reportedly have had blood transfusions or blood 
products previously. Like hepatitis B, hepatitis C has high risk to develop to chronic 
liver diseases including cirrhosis and hepatocellular carcinoma in up to 85% of cases in 
Malaysia (Ministry of Health Malaysia, 2005). 
 
There are many routes of HCV transmission including blood transfusion which is 
considered as the current risk of infection by HCV. Moreover, an important percentage 
of the infected people can acquire the virus by drug use through injections. Direct 
exposure to infected blood, sex with multiple partners, tattoos, perinatal transmission 
and hemodialysis are considering important routes in HCV transmission. Moreover, it is 
estimated that 2% of people are infected with HCV through the needle stick injury 
(Lamoreux, 2008). 
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Preventing the progression to severe liver disease by the early eradication of the HCV is 
the main goal of hepatitis C treatment (Strader et al., 2004). The majority of infected 
people are mostly unable to clear the infection because there is no known drug which 
can eradicate the HCV. Nevertheless, HCV infection treatment includes antiviral and 
immunomodulatory agents that modify the immune response and suppress the viral 
replication. Interferon is the only potential treatment that can be used effectively to 
inhibit the viral replication and minimize liver injury in a minority of patients but the 
improvement is usually transient. The most successful treatment has been measured by 
its ability to improve the liver histological findings and normalization of ALT levels in 
the serum (Sharara et al., 1996). Using a combination treatment of ribavarine and 
interferon may improve the patients’ response and the therapy effectiveness (Armas-
Merino et al., 1999). 
 
1.3   Diabetes Mellitus 
In 2000, according to the WHO, the estimated number of people diagnosed with diabetes 
mellitus (DM) was approximately 177 million worldwide and the expectations predict an 
increase in diabetic patients to at least 300 million by 2025. Thus, according to these 
statistics, there will be 165% increase in the DM incidence in the next 25 years 
(American Diabetes Association, 2004). In developing countries, most of people with 
DM belong to age group of 45 – 65 years. The DM management costs are ranging from 
2.5% to 15% of the annual national health care budgets (American Diabetes Association, 
2005).  
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It was reported that 5.1% of people with ages ranging between 20 -79 years in all 
International Diabetes Federation (IDF) member countries have DM in 2003 (American 
Diabetes Association, 2004). The highest numbers of people with DM are in the 
European Region and Pacific Region and these numbers are about 48 and 43 million 
respectively. The prevalence rate of DM in the North American region is considered as 
the highest rate which is 7.9% followed by the European region (7.8%) (American 
Diabetes Association, 2005). 
 
In Asia, China and India are considered the most populous countries in the world in 
which give these two countries the prime importance to the epidemiology of DM. WHO 
predicts that the number of diabetic cases will increase in these two countries 
substantially. The majority of these cases will be in China (50 million) and India (57 
million), therefore, more than 30% of people with DM will be in these two countries 
alone in 2025 (Cockram, 2000). 
 
In Malaysia, the First National Health and Morbidity Survey (NHMS 1) was conducted 
in 1986 and reported the DM prevalence of 6.3%, while in the Second National Health 
and Morbidity Survey (NHMS 2) in 1996 the prevalence elevated to 8.2%. In a recent 
study, the prevalence had been noted to be higher at 10.5%. The WHO has predicted that 
Malaysia would have a total number of 2.48 million diabetics in 2030 compared to 0.94 
million in 2000 increased by 164% (Mafauzy, 2006).  
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Malaysia is a multiethnic population and it consists of three main races Malay, Chinese 
and Indian and all these races are well represented in this country. Therefore, taking all 
together, Malaysian population would be at a higher risk to develop DM phenomenally 
like other countries in Asia (Zaini, 2000). 
 
There are two types of DM; type-1 (insulin dependent diabetes mellitus i.e. IDDM) and 
type-2 (non-insulin-dependent diabetes mellitus i.e. NIDDM). Type-1 diabetes occurs 
mostly in children and young adults and can be noted in different ages. Approximately 
4.9 million people are diagnosed with IDDM in various age groups, in which, its 
prevalence in the world’s population is about 0.09%. The European Region has the 
highest number of IDDM cases 1.27 million, while the number in the North American 
Region is 1.04 million and in the South East Asian Region is 0.91 million patients with 
IDDM (Tabibiazar and Edelman, 2003). 
 
NIDDM is the most common form of DM in the world and approximately 90% of DM 
patients are with NIDDM (Vijan et al., 2000). The main factors that can be associated 
with the NIDDM occurrence are older age, family history, obesity, previous history of 
gestational diabetes, ethnicity and physical inactivity. The nature of the epidemic of DM 
still affects an increasing number of people worldwide, while global awareness remains 
low. In developed countries, NIDDM composes about 85% to 95% of all cases with DM 
and it constitutes for a higher percentage in the developing countries (International 
Diabetes Federation, 2003).  
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The NIDDM symptoms progress gradually in the diabetic patients and their onset does 
not suddenly happen like in IDDM. The symptoms of NIDDM may include nausea, 
polyuria, fatigue, weight loss, unusual thirst, frequent infections, blurred vision and slow 
healing of wounds, while other people may have no symptoms at all (Misra and Vikram, 
2004).  
 
In many countries, most of the DM cases are intensified in the urban areas. This feature 
will be destined to increase especially in countries with fast industrialization in the 
future (American Diabetes Association, 2005). In the developing countries, the situation 
is considered as a significant predictor for the projected increasing in numbers of DM 
cases. DM prevalence is higher in the developed world countries than in the developing 
countries, it is predicted to remain so till 2025. Therefore, the developing world will bear 
the burden of the increasing epidemic in the future. This problem should be addressed 
and solved, otherwise, the DM prevalence in the developing countries is predicted to rise 
by 170% in 2025 while the rise in the developed countries is at 41% over the same 
period (American Diabetes Association, 2004). 
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1.4  Association of Chronic Viral Hepatitis Infection and Type-2 Diabetes  
The occurrence of DM has been reported to be higher in patients with chronic hepatitis 
that resulted from different etiologies when compared with the general population 
(Huang et al., 2010). The liver’s role in the carbohydrate metabolism is considered as 
substantial and important, so any defects in the liver functions may cause glycemic 
homestasis abnormalities as a complication of chronic liver disease (Custro et al., 2001). 
 
Clinically, the risk of having NIDDM in chronic HCV infected patients is important 
even though it is small. The liver disease progression is noticed to be deteriorated in the 
presence of DM and the effectiveness of viral hepatitis treatment agents can be less. 
NIDDM has been considered as an extrahepatic manifestation of HCV infection based 
on early clinical observations. Although the mechanism by which the HCV lead to DM 
are still not well determined, the direct virus action or cytokine stimulation are 
considered as suggested mechanisms that enhance the HCV infection to develop 
NIDDM in the infected patients (White et al., 2008).  
 
Further investigation into the pathophysiologies of that association may help to find out 
the main process by which NIDDM can occur in HCV infected patients (Wilson, 2004). 
Based on investigations which have reported that NIDDM occurrence will be decreased 
as a result of curing of HCV infection, clinical trials of chronic HCV infection treatment 
have shown that HCV may interact with the carbohydrates metabolism in the infected 
people (Negro and Clément, 2010). Many studies have revealed that the frequency of 
NIDDM in patients infected with chronic HCV is higher as compared with chronic HBV 
or other chronic liver diseases. Moreover, this higher prevalence of DM is not linked 
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exclusively to liver cirrhosis as it is increased in non-cirrhotic patients with HCV 
infection when compared to non-cirrhotic patients with HBV infection (Petit et al., 
2001). The prevalence of NIDDM is estimated 9-50% among HCV infected patients 
(Mavrogiannaki et al., 2009). At a conservative estimation, approximately 12 million 
patients with HCV-induced cirrhosis and 28 million with chronic HCV have DM, 
therefore, HCV infection can develop DM in about 40 million individuals leading to a 
major public health problem (Lecube et al., 2004).  
 
Many risk factors can be involved to exaggerate the expression of NIDDM in HCV 
infected patients like age, body mass index, race, family history of DM and liver 
cirrhosis. Furthermore, people who they are 40 years old and above with HCV infection 
were reported to have NIDDM three times than those without HCV infection according 
to the Third National Health and Nutrition Examination Survey (NHANES III) (Mehta 
et al., 2000).  
 
Recent studies have suggested that liver transplantation which has been caused by HCV 
infection is substantially associated with post-transplant NIDDM occurrence (Mugo et 
al., 2006). Moreover, approximately 40-64% of HCV infected liver transplantation 
recipients have developed post-transplant NIDDM and this prevalence is higher than that 
of transplanted patients for other liver diseases. In other words, hepatitis C infection has 
been reported to be a significant independent risk factor for occurrence of post-liver 
transplant DM (Lecube et al., 2006).  
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On the other hand, many other studies have revealed that HBV infection may also cause 
DM, but the frequencies of this connection are less than in HCV infection (Mason et al., 
1999). Although there is a link between HCV infection and NIDDM and it has been 
recognized, there is correlation between chronic HBV infection and NIDDM can still be 
detected. However, since chronic viral hepatitis has been caused by both HBV and 
HCV, and in addition to the high prevalence of HBV infection as well as DM, combined 
with HCV- NIDDM link, it is possible that chronic HBV infection can develop NIDDM 
in HBV infected patients (Li-Ng et al., 2007). In spite of there are several data which 
have shown that HBV infection has less significance association with NIDDM than 
HCV infection, chronic HBV infection can have a significant role in the development of 
NIDDM (Lao et al., 2007). Based on several studies, the association between HBV 
infection and NIDDM can be attributed to the complications of HBV infection including 
liver fibrosis or cirrhosis (Huang et al., 2010). While in other studies, the NIDDM 
occurrence can be detected in chronic HBV infected patients in the absence of liver 
cirrhosis with DM prevalence estimated 2-14% among the HBV population 
(Mavrogiannaki et al., 2009). 
 
1.4.1  Pathophysiological Mechanisms for Development of Type-2 Diabetes in 
Hepatitis C Virus Infection 
The specific mechanisms responsible for the development of NIDDM in HCV infected 
patients are still unknown. The main mechanisms that may be proposed in the HCV 
infection-DM association could be the direct damage to the pancreatic beta cell, the 
triggering of beta cell autoimmunity by HCV and/or the increased in the insulin 
resistance (Noto and Raskin, 2006). 
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1.4.1.1 Beta Cell Autoimmunity 
HCV is associated with extrahepatic events of autoimmune origin such as the 
glomerulonephritis membranoproliferative and essential mixed cryoglobulinemia. HCV 
infection may trigger an autoimmune reaction against pancreatic beta cells leading to 
DM. HCV can also stimulate these cells by having a region of its amino acid sequence 
shows a strong homology with glutamic acid decarboxylase (GAD) which is the most 
important pancreatic islet cell antigen. This mechanism can contribute in the occurrence 
of DM in HCV infected patients but it is not considered as the main pathophysiology of 
HCV infection and DM association (Honeyman et al., 1998). 
 
1.4.1.2 Direct Injury of the Beta Cell  
Although HCV mainly affects the liver (Aria et al., 1993), its occurrence in other tissues 
confirms that viral replication can also infect other organs. It has been able to detect 
multiple replications in extrahepatic sites such as mononuclear cells, Lymph nodes, 
brain, adrenal gland, heart, kidney, intestine, thyroid, bone marrow, spleen and pancreas 
(Vargas et al., 2002). Virtually, an active replication of HCV in has been reported in the 
acinar cells of exocrine pancreas and in the epithelial cells of the pancreatic 
ducts. However, it is possible that HCV can infect the pancreatic beta cells and interfere 
in the synthesis and secretion of insulin leading to DM (Yan et al., 2000).  
  
1.4.1.3 Insulin Resistance in Hepatitis C Infection 
It stands to reason that HCV infection leads to increase the insulin resistance because it 
is an infectious process that produces liver injury (Konrad et al., 2000). However, there 
must be some specific mechanisms associated with HCV infection causing a higher 
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prevalence of DM compared to other liver diseases. Although the pathophysiology of 
insulin resistance has been reported as the basic mechanism for developing NIDDM in 
chronic HCV infected patients, it is not confirmed that production of proinflammatory 
cytokines could be responsible for the greatest potential DM in HCV infected patients 
(Lecube et al., 2006). 
 
It is well known that insulin resistance is associated with increased proinflammatory 
activity with elevated cytokine such as tumor necrosis factor alpha (TNF-α) and 
interleukin-6 (IL-6) (Bugianesi et al., 2005). The TNF-α promotes serine 
phosphorylation of the substrate-1-insulin receptor, decreasing the activity of this 
receptor tyrosine kinase (Hotamisligil et al., 1996), and its expression is directly related 
to insulin resistance and hypertriglyceridemia (Kern et al., 2001). The TNF-α exerts its 
biological effects through interaction with two types of receptors that are expressed in 
the cell membrane, type 1 (TNFR1) and type 2 (TNFR2) (Tartaglia and Goeddel, 
1992). Quantification plasma of the two receptors is the best indicator of the overall 
system activation, having a longer half-life, higher plasma levels and less variability 
than TNF-α (Straczkowski et al., 2002).  
 
For its part, the IL-6 is a multifunctional cytokine produced by a variety of cell types, 
including immune system, liver and adipose tissue. It mediates both the inflammatory 
reaction and in the response induced by stress (Papanicolaou et al., 1998). The IL-6 
promotes the insulin resistance through inhibition of transcription of the glucose 
transporter GLUT-4 which is a substrate of the insulin receptor (Rotter et al., 
2003). Circulating levels of IL-6 are associated with insulin resistance in human with 
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NIDDM (Vozarova et al., 2001) and predict the risk of developing DM (Hotamisligil et 
al., 1996). In comparison with the healthy individuals, patients with chronic HCV 
infection have showed extra concentrations of both TNF-α and its soluble receptors 
(sTNFR1 and sTNFR2) and IL-6 (Knobler and Schattner, 2005; Malaguarnera et al., 
1997). In addition, it has reported that the concentration of these cytokines is associated 
with the severity degree of liver injury (Neuman et al., 2002). However, to date no 
studies have evaluated the relationship between TNF-α, sTNFR1, sTNFR2 and IL-6 
with insulin resistance and/or DM in patients infected with HCV infection compared 
with patients with other liver diseases (Lecube et al., 2006).  
 
In summary, HCV infection by direct virus action and induce liver inflammation, cause 
releasing and activation of TNF-α and IL-6, then by mechanisms above, leading to 
insulin resistance then to NIDDM. Other factors of the host including age, obesity and 
positive family history of DM, may help in insulin resistance develop by increasing the 
level of TNF-α or by other different mechanisms (Schattner and Knobler, 2008). 
 
1.4.2  Risk Factors for Hepatitis C Infection-Diabetes Association 
Patients with chronic hepatitis infection are considered at high risk to develop NIDDM 
substantially (Qureshi et al., 2002). In addition, there are many predisposing factors 
which can aggravate the occurrence of DM in hepatitis patients such as age, obesity, 
race, positive family history and severe hepatic histology (Schattner and Knobler, 2008). 
In chronic HCV infected patients, NIDDM occurs more frequently in persons who are 
older, with high BMI and non-white (Mehta et al., 2000). The trend of the recent studies 
is to focus on the association of HCV infection and NIDDM and the independent risk 
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factors for DM development in patients with chronic HCV infection. According to these 
studies, many factors were reported to develop NIDDM and others were found not 
affecting on its occurrence (Fartoux et al., 2005).  
 
According to clinical evidences, age can play an important role in the occurrence of 
NIDDM in HCV infected patients and it can be as a predisposing factor for getting DM 
in general population, as well as in HCV infected patients. Obesity is considered as one 
of the important risk factors leading to DM, and it was also found to be one of the 
contributors in developing NIDDM in HCV infected population. Many studies have 
shown that obesity was highly associated with NIDDM occurrence (Knobler and 
Schattner, 2005).  
 
In addition, HCV infected patients with positive family history of DM will be at a higher 
risk of having NIDDM. It was noticed that the family history of DM was the most 
significant predictor for NIDDM occurrence in patients with chronic HCV infection 
(Chehadeh et al., 2009). Furthermore, patients with acute alcoholic consumption may be 
at a risk of having DM by the reduction in insulin-mediated glucose uptake. While the 
chronic drinking of alcohol will lead to damage of the pancreatic islet β-cells causing 
NIDDM (Garcia-Compean et al., 2009).  
 
The other risk factor which is leading to NIDDM in HCV infected patient is race. Many 
data have recognized that patients who are black can develop NIDDM that associated 
with HCV infection. Moreover, the prevalence of NIDDM has been shown to be 
increased significantly in blacks with HCV infection. Additionally, HCV infection may 
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increase the occurrence of NIDDM in blacks since this race is at a higher risk due to 
insulin resistance, dysfunction of islet cell and the genetics interplay. Accordingly, HCV 
infection- NIDDM link was measured in different ethnic group like Japanese, American 
Indian, Chinese and Italian. As a result of the environmental factors effect, the 
association of HCV and NIDDM can be differed in these ethnic groups (Mugo et al., 
2006).  
 
Recently, the importance of risk factors identification is to reveal by which mechanism 
this association happens (Petit et al., 2001). Furthermore, HCV infection is considered 
as an important factor to cause liver cirrhosis and the latter was found to be highly 
associated with glucose intolerance. Approximately 10-20% patients with cirrhosis may 
have DM as one of the liver cirrhosis complications (Schattner and Knobler, 2008). 
 
1.4.3  Complications of Hepatitis C Infection and Diabetes Comorbidity  
The association of HCV infection and NIDDM has several clinical consequences 
regardless of the association pathogenesis (Leandro et al., 2006). Moreover, the stage of 
liver cirrhosis severity depends on many cofactors including gender, age, obesity and 
clinical conditions. NIDDM is considered as one of these cofactors which may affect on 
the HCV infection and modify its course leading to worsen the prognosis of HCV 
infection (Negro and Clément, 2010). DM morbidity is severe and affects on people life 
seriously due to many complications including fibrosis, liver failure, minimum response 
to the antiviral therapy and development of hepatocellular carcinoma. According to 
recent studies, DM can cause severe hepatic encephalopathy in HCV cirrhotic patients 
compared to patients without DM (Lonardo et al., 2007).  
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Furthermore, DM has been reported to develop liver cancer in cirrhotic patients with 
chronic HCV infection. These evidences show that the DM interacts with other 
traditional risk factors and with HCV infection to increase the risk of hepatocellular 
carcinoma occurrence (Lonardo et al., 2007). In addition, many factors may be included 
in liver cancer development such as HCV infection, HBV infection, cirrhosis as well as 
NIDDM which all of these are more frequent in patients with primary liver cancer. DM 
can cause a primary liver cancer in the existence of other risk factors including HBV, 
HCV infection and liver cirrhosis, i.e. that DM has increased the possibility for 
developing hepatocellular carcinoma in patients with chronic liver disease. Other risk 
factors such as gender, age and alcohol intake may contribute to develop hepatocellular 
carcinoma in the presence of DM and HCV infection (Mugo et al., 2006). 
 
Moreover, HCV  infected patients are at a high risk of insulin resistance, which in turn, 
may consider as independent risk factor for liver fibrosis, since fibrosis grades were 
significantly linked to insulin resistance. Recently, evidence has confirmed that insulin 
resistance occurs at early stages of HCV infection and it is considered as an independent 
predictor for liver fibrosis degree (Hui et al., 2003). According to this observation, 
patients who were infected with HCV and developed DM may have severe hepatitis 
complications based on their liver enzymes and liver biopsy findings (Petit et al., 2001). 
 
In general, DM is well known to cause microvascular and macrovacular complications, 
therefore, HCV patients with DM will be more risked to develop these complications. It 
has been reported that patients with DM may develop severe renal dysfunction in the 
presence of HCV infection than in patients without HCV infection (Soma et al., 2000). 
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In addition, hemodialysis has been shown to be required in one third of chronic hepatitis 
patients. Recently, both DM and atherosclerosis can be attributed to inflammatory cause 
and the occurrence of both can be increased and worsened as a result of severe 
inflammation (Pradhan et al., 2001). Moreover, the increase in the TNF level has been 
recognized to be related with recurrent vascular events and atherosclerosis (Ridker et al., 
2000). Since the chronic hepatitis infection is associated with TNF level increasing in 
the liver and serum, the association of HCV and DM can be significantly linked to more 
deteriorated vascular complications than in each disorder alone (Schattner and Knobler, 
2008). 
 
1.4.4  Clinical Management 
The understanding of treatment concepts of HCV- NIDDM association is still unclear 
and partially understood. There are two main purposes of treating the DM in HCV 
infection: to minimize the fibrogensis, thus, the progression of liver disease and to 
improve the response to antiviral therapy (Negro and Clément, 2010). Similarly, the 
eradication of HCV by antiviral therapy such as interferon can decrease the insulin 
resistance and improve the insulin sensitivity. However, the reported response is below 
the required level, therefore, further studies are needed in order to improve the response 
to antiviral therapy (Strader et al., 2004). One of the most important therapy concepts is 
to correct the insulin resistance, since HCV infection has been reported to increase the 
insulin resistance which can predispose for development of DM and interfere with the 
course of liver disease. Thus, the clearance of HCV infection is leading to decrease the 
insulin resistance and reduce the possibility of DM occurrence and liver complications 
(Alaei and Negro, 2008).  
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Furthermore, the insulin resistance must be reduced in patients with HCV infection who 
are not responding to interferon therapy in order to increase the response to the antiviral 
therapy upon retreatment. However, the improvement of response to interferon therapy 
has been recognized by insulin sensitizing agents (Overbeck et al., 2008).  
 
Other evidences have shown that weight loss in chronic HCV infected patients may 
contribute to the decrease the liver enzymes and reduce liver fibrosis (Hickman et al., 
2002). While in other studies, it has been reported that insulin sensitivity can be 
increased by TNF-α inhibition (Shintani et al., 2004). Further studies are needed to 
investigate the proper treatment used for insulin sensitivity improvement and to evaluate 
the association of these insulin sensitizing agents with HCV infection by various 
pharmacological intervention (Schattner and Knobler, 2008). 
 
1.5   Problem Statement 
For many years, people have debated about the chronic viral hepatitis and DM 
association. Patients with chronic viral hepatitis infection can be under a great risk to 
develop DM especially in those patients with pre-diabetes factors. However, the 
ignorance of this problem may lead to serious complications with increased mortality 
rate among the hepatitis population. All these prompt the efforts to investigate the 
occurrence of DM and the associated risk factors among the chronic viral hepatitis 
infected Malaysian patients.  
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1.6   Rationale of the Study  
The link between chronic viral hepatitis and DM occurrence is considered substantial, 
therefore, many questions must still be addressed related to this association between 
these two common public health problems. To current date, there is no published data 
that investigate the association between NIDDM and chronic viral hepatitis in Malaysia. 
Based on this fact, the current study is aimed to evaluate the epidemiological connection 
between chronic HBV and HCV with NIDDM occurrence among the Malaysian 
population. In addition, this study investigates the associated factors with the 
development of NIDDM among the HBV and HCV population of the study.  
 
1.7   Significance of the Study 
The results of this study could be used as a baseline for future studies that focused on the 
association between chronic viral hepatitis and NIDDM. Furthermore, this study may 
support the background of the practitioners about the possibility of NIDDM occurrence 
in chronic viral hepatitis patients, especially HCV infection. It could also help to reduce 
the DM occurrence in chronic hepatitis patients by attracting the attention of the 
involved individuals to prevent the NIDDM development among the chronic viral 
hepatitis patients and to avoid the clinical complications of the HCV infection- NIDDM 
association. On the other hand, this study will give an idea for the HCV infected 
patients, especially those who they have other associated risk factors, about the 
possibility of having NIDDM and severe clinical consequences due to that combination.  
 
